Recent advances in polymer-based wound dressings for the treatment of diabetic foot ulcer

An overview of state-of-the-art

Zahid Hussain, Hnin Ei Thu, Ahmad Nazrun Shuid, Haliza Katas, Fahad Hussain

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Background: Diabetic foot ulcers (DFUs) are the chronic, non-healing complications of diabetic mellitus which compels a significant burden to the patients and the healthcare system. Peripheral vascular disease, diabetic neuropathy, and abnormal cellular and cytokine/chemokine activity are among the prime players which exacerbate the severity and prevent wound repair. Unlike acute wounds, DFUs impose a substantial challenge to the conventional wound dressings and demand the development of novel and advanced wound healing modalities. In general, an ideal wound dressing should provide a moist wound environment, offer protection from secondary infections, eliminate wound exudate and stimulate tissue regeneration. Objective: To date, numerous conventional wound dressings are employed for the management of DFUs but there is a lack of absolute and versatile choice. The current review was therefore aimed to summarize and critically discuss the available evidences related to pharmaceutical and therapeutic viability of polymer-based dressings for the treatment of DFUs. Results: A versatile range of naturally-originated polymers including chitosan (CS), hyaluronic acid (HA), cellulose, alginate, dextran, collagen, gelatin, elastin, fibrin and silk fibroin have been utilized for the treatment of DFUs. These polymers have been used in the form of hydrogels, films, hydrocolloids, foams, membranes, scaffolds, microparticles, and nanoparticles. Moreover, the wound healing viability and clinical applicability of various mutually modified, semi-synthetic or synthetic polymers have also been critically discussed. Conclusion: In summary, this review enlightens the most recent developments in polymer-based wound dressings with special emphasis on advanced polymeric biomaterials, innovative therapeutic strategies and delivery approaches for the treatment of DFUs.

Original languageEnglish
Pages (from-to)527-550
Number of pages24
JournalCurrent Drug Targets
Volume19
Issue number5
DOIs
Publication statusPublished - 1 Apr 2018

Fingerprint

Diabetic Foot
Bandages
Polymers
Wounds and Injuries
Fibroins
Therapeutics
Tissue regeneration
Silk
Wound Healing
Elastin
Chitosan
Colloids
Biocompatible Materials
Hyaluronic Acid
Gelatin
Dextrans
Fibrin
Chemokines
Scaffolds
Cellulose

Keywords

  • Conventional dressings
  • Diabetic foot ulcer
  • Efficacy-upgradation
  • Natural and synthetic polymers
  • Non-linear wound healing

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Recent advances in polymer-based wound dressings for the treatment of diabetic foot ulcer : An overview of state-of-the-art. / Hussain, Zahid; Thu, Hnin Ei; Shuid, Ahmad Nazrun; Katas, Haliza; Hussain, Fahad.

In: Current Drug Targets, Vol. 19, No. 5, 01.04.2018, p. 527-550.

Research output: Contribution to journalReview article

@article{91747732ec8b4e268a0f21fac0fad573,
title = "Recent advances in polymer-based wound dressings for the treatment of diabetic foot ulcer: An overview of state-of-the-art",
abstract = "Background: Diabetic foot ulcers (DFUs) are the chronic, non-healing complications of diabetic mellitus which compels a significant burden to the patients and the healthcare system. Peripheral vascular disease, diabetic neuropathy, and abnormal cellular and cytokine/chemokine activity are among the prime players which exacerbate the severity and prevent wound repair. Unlike acute wounds, DFUs impose a substantial challenge to the conventional wound dressings and demand the development of novel and advanced wound healing modalities. In general, an ideal wound dressing should provide a moist wound environment, offer protection from secondary infections, eliminate wound exudate and stimulate tissue regeneration. Objective: To date, numerous conventional wound dressings are employed for the management of DFUs but there is a lack of absolute and versatile choice. The current review was therefore aimed to summarize and critically discuss the available evidences related to pharmaceutical and therapeutic viability of polymer-based dressings for the treatment of DFUs. Results: A versatile range of naturally-originated polymers including chitosan (CS), hyaluronic acid (HA), cellulose, alginate, dextran, collagen, gelatin, elastin, fibrin and silk fibroin have been utilized for the treatment of DFUs. These polymers have been used in the form of hydrogels, films, hydrocolloids, foams, membranes, scaffolds, microparticles, and nanoparticles. Moreover, the wound healing viability and clinical applicability of various mutually modified, semi-synthetic or synthetic polymers have also been critically discussed. Conclusion: In summary, this review enlightens the most recent developments in polymer-based wound dressings with special emphasis on advanced polymeric biomaterials, innovative therapeutic strategies and delivery approaches for the treatment of DFUs.",
keywords = "Conventional dressings, Diabetic foot ulcer, Efficacy-upgradation, Natural and synthetic polymers, Non-linear wound healing",
author = "Zahid Hussain and Thu, {Hnin Ei} and Shuid, {Ahmad Nazrun} and Haliza Katas and Fahad Hussain",
year = "2018",
month = "4",
day = "1",
doi = "10.2174/1389450118666170704132523",
language = "English",
volume = "19",
pages = "527--550",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Recent advances in polymer-based wound dressings for the treatment of diabetic foot ulcer

T2 - An overview of state-of-the-art

AU - Hussain, Zahid

AU - Thu, Hnin Ei

AU - Shuid, Ahmad Nazrun

AU - Katas, Haliza

AU - Hussain, Fahad

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Diabetic foot ulcers (DFUs) are the chronic, non-healing complications of diabetic mellitus which compels a significant burden to the patients and the healthcare system. Peripheral vascular disease, diabetic neuropathy, and abnormal cellular and cytokine/chemokine activity are among the prime players which exacerbate the severity and prevent wound repair. Unlike acute wounds, DFUs impose a substantial challenge to the conventional wound dressings and demand the development of novel and advanced wound healing modalities. In general, an ideal wound dressing should provide a moist wound environment, offer protection from secondary infections, eliminate wound exudate and stimulate tissue regeneration. Objective: To date, numerous conventional wound dressings are employed for the management of DFUs but there is a lack of absolute and versatile choice. The current review was therefore aimed to summarize and critically discuss the available evidences related to pharmaceutical and therapeutic viability of polymer-based dressings for the treatment of DFUs. Results: A versatile range of naturally-originated polymers including chitosan (CS), hyaluronic acid (HA), cellulose, alginate, dextran, collagen, gelatin, elastin, fibrin and silk fibroin have been utilized for the treatment of DFUs. These polymers have been used in the form of hydrogels, films, hydrocolloids, foams, membranes, scaffolds, microparticles, and nanoparticles. Moreover, the wound healing viability and clinical applicability of various mutually modified, semi-synthetic or synthetic polymers have also been critically discussed. Conclusion: In summary, this review enlightens the most recent developments in polymer-based wound dressings with special emphasis on advanced polymeric biomaterials, innovative therapeutic strategies and delivery approaches for the treatment of DFUs.

AB - Background: Diabetic foot ulcers (DFUs) are the chronic, non-healing complications of diabetic mellitus which compels a significant burden to the patients and the healthcare system. Peripheral vascular disease, diabetic neuropathy, and abnormal cellular and cytokine/chemokine activity are among the prime players which exacerbate the severity and prevent wound repair. Unlike acute wounds, DFUs impose a substantial challenge to the conventional wound dressings and demand the development of novel and advanced wound healing modalities. In general, an ideal wound dressing should provide a moist wound environment, offer protection from secondary infections, eliminate wound exudate and stimulate tissue regeneration. Objective: To date, numerous conventional wound dressings are employed for the management of DFUs but there is a lack of absolute and versatile choice. The current review was therefore aimed to summarize and critically discuss the available evidences related to pharmaceutical and therapeutic viability of polymer-based dressings for the treatment of DFUs. Results: A versatile range of naturally-originated polymers including chitosan (CS), hyaluronic acid (HA), cellulose, alginate, dextran, collagen, gelatin, elastin, fibrin and silk fibroin have been utilized for the treatment of DFUs. These polymers have been used in the form of hydrogels, films, hydrocolloids, foams, membranes, scaffolds, microparticles, and nanoparticles. Moreover, the wound healing viability and clinical applicability of various mutually modified, semi-synthetic or synthetic polymers have also been critically discussed. Conclusion: In summary, this review enlightens the most recent developments in polymer-based wound dressings with special emphasis on advanced polymeric biomaterials, innovative therapeutic strategies and delivery approaches for the treatment of DFUs.

KW - Conventional dressings

KW - Diabetic foot ulcer

KW - Efficacy-upgradation

KW - Natural and synthetic polymers

KW - Non-linear wound healing

UR - http://www.scopus.com/inward/record.url?scp=85041384616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041384616&partnerID=8YFLogxK

U2 - 10.2174/1389450118666170704132523

DO - 10.2174/1389450118666170704132523

M3 - Review article

VL - 19

SP - 527

EP - 550

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 5

ER -